• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ORTHO-CLINICAL DIAGNOSTICS VITROS CHEMISTRY PRODUCTS PHYT SLIDES; IN VITRO DIAGNOSTICS

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ORTHO-CLINICAL DIAGNOSTICS VITROS CHEMISTRY PRODUCTS PHYT SLIDES; IN VITRO DIAGNOSTICS Back to Search Results
Catalog Number 8298671
Device Problem High Test Results (2457)
Patient Problem No Known Impact Or Consequence To Patient (2692)
Event Date 10/01/2018
Event Type  malfunction  
Manufacturer Narrative
The investigation determined that higher than expected vitros phenytoin (phyt) results were obtained on a patient sample and a quality control (qc) fluid and a higher than expected vitros carbamazepine (crbm) result was obtained from a patient sample when tested using vitros chemistry products phyt slides and vitros chemistry products crbm slides in combination with two different vitros 5600 integrated systems.The most likely assignable cause of the event was a sample related issue.The affected patient correlation samples appeared to be slightly viscous, although no sample metering condition codes were generated when the samples were processed.In addition, some samples may have been stored refrigerated for up to 2 weeks.However, the samples used for the vitros phyt correlation were plasma samples stored refrigerated on average for 7 days, while the vitros crbm correlation were plasma samples stored refrigerated on average for 5 days.Per the vitros phyt instructions for use (ifu), samples can be stored refrigerated for =7 days, while per the vitros crbm ifu, samples can be stored refrigerated for =5 days.Improper sample handling could not be ruled out as contributing to the event as no information was provided concerning the centrifugation procedure or if the samples were centrifuged a second time prior to the retesting events.It is possible that cellular debris, due to poor sample preparation, was present in the affected samples, although this could not be confirmed.A review of vitros phyt quality control results processed on (b)(4) did show some imprecision within the timeframe of the event.Therefore, an instrument or slide related issue cannot be completely ruled out for the higher than expected vitros phyt results.Ongoing tracking and trending of complaints has not identified any signals that would suggest there is a systemic issue with either vitros phyt reagent lot 2617-0168-2514 or vitros crbm reagent lot 3942-0102-0838.The customer later processed four alternate patient samples and both biorad qc levels on analyzer (b)(4) using both lots of immunowash fluid (iwf) and vitros phyt slides.They also ran an additional four patient samples and both biorad qc levels on analyzer (b)(4) using both lots of iwf and vitros crbm slides.All correlation patient results were deemed acceptable.
 
Event Description
A customer obtained higher than expected results on patient samples used for correlation testing between a previous and new lot of immunowash fluid (iwf).The patient samples were tested using vitros chemistry products phenytoin (phyt) slides and vitros chemistry products carbamazepine (crbm) slides on two different vitros 5600 integrated systems.A higher than expected quality control fluid result was discovered later.Vitros phyt slide lot 2617-0168-2514 tested on (b)(4).Patient sample a vitros phyt result of 42.8 umol/l vs.The expected result of 29.6 umol/l.Vitros phyt slide lot 2617-0168-2514 tested on (b)(4).Non-vitros biorad immunoassay plus control lot 27730 l3 vitros phyt result of 147.5 umol/l vs.The expected result of 113.0 umol/l.Vitros crbm slide lot 3942-0102-0838 tested on (b)(4).Patient sample q vitros crbm result of 64.8 umol/l vs.The expected result of 44.3 umol/l.Biased results of the magnitude and direction observed may lead to inappropriate physician action if they were to occur undetected on patient samples.The vitros phyt and crbm results were not reported outside the lab.There were no allegations of patient harm as a result of this event.This report is number 1 of 3 mdr¿s for this event.Three (3) 3500a forms are being submitted for this event as 3 devices were involved.This report corresponds to ortho clinical diagnostics inc.Complaint numbers (b)(4).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
VITROS CHEMISTRY PRODUCTS PHYT SLIDES
Type of Device
IN VITRO DIAGNOSTICS
Manufacturer (Section D)
ORTHO-CLINICAL DIAGNOSTICS
100 indigo creek drive
rochester NY 14626
Manufacturer (Section G)
ORTHO-CLINICAL DIAGNOSTICS
513 technology blvd.
rochester NY 14652
Manufacturer Contact
james a stevens
100 indigo creek drive
rochester, NY 14626
5854533000
MDR Report Key8181031
MDR Text Key131911876
Report Number1319809-2018-00166
Device Sequence Number1
Product Code DIP
Combination Product (y/n)N
Reporter Country CodeCA
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional,o
Reporter Occupation Other
Type of Report Initial
Report Date 12/19/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received12/19/2018
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date01/15/2019
Device Catalogue Number8298671
Device Lot Number2617-0168-2514
Was Device Available for Evaluation? Yes
Date Manufacturer Received11/23/2018
Was Device Evaluated by Manufacturer? Yes
Date Device Manufactured08/25/2018
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage N
Patient Sequence Number1
-
-